Company profile
Unicycive Therapeutics, Inc.
NASDAQ: UNCY · Healthcare · Biotechnology
#906 of 1,418 Healthcare companies by revenuebottom-quartile growth
EA Score
32DFH 36DQ 23GM —SS 41
v0.1 · 55/100 weight · provisional
↑ market scale, balance-sheet leverage · ↓ disclosure history, operating margin
Methodology →Revenue TTM
$0
Rev growth YoY (TTM)
needs 8 qtrs
Net income (FY)
-$26.6M
Employees
21
as of 2026-08-14
Market cap
$144.2M
as of 2026-08-14
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$675.0k$675.0k2023
Net income-$26.6M-$26.6M2025
Operating income-$29.5M-$29.5M2025
Total assets$49.1M$49.1M2025
Liabilities$18.9M$18.9M2025
Equity$30.2M$30.2M2025
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Unicycive Therapeutics, Inc.’s revenue?
Unicycive Therapeutics, Inc. booked $675.0k in FY2023 revenue, contracting 29% year over year — slower than 75% of Healthcare companies we track, at a -3934.1% net margin.
Peers · Healthcare
Lexaria Bioscience Corp.44DHarvard Apparatus Regenerative Technology Inc.41DAdia Nutrition, Inc.29DSETO Holdings, Inc.54DLexeo Therapeutics, Inc. Common Stock37DPolomar Health Services, Inc.28DNeighbors
Santa Clara →Key facts
CEOShalabh K. Gupta
SectorHealthcare
IndustryBiotechnology
HeadquartersLos Altos, CA
ExchangeNASDAQ: UNCY
Employees21
IPO date2021-07-12
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.